REPLLawsuits•prnewswire•
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
Sentiment:Negative (-70)
Summary
(NASDAQ:REPL) SAN FRANCISCO, Sept. 4, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives. The lawsuit alleges that the company misled investors by overstating the success of its lead cancer drug, RP1, leading to a...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 4, 2025 by prnewswire